Dr. McDermott on the Use of Anti–PD-1 Combinations in mRCC

David F. McDermott, MD, discusses the use of PD-1 inhibitors in combination with VEGF inhibitors and CTLA-4 inhibitors in metastatic renal cell carcinoma.

Website:
Twitter:
Facebook:
LinkedIn:

cancer,oncology,